Stock Performance Review on Pfizer and Three Other Drug Makers Stocks

Stock Research Monitor: GSK, MRK, and NVS

LONDON, UK / ACCESSWIRE / June 26, 2018 / If you want a free Stock Review on PFE sign up now at www.wallstequities.com/registration. On Monday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 2.09%; the Dow Jones Industrial Average edged 1.33% lower; and the S&P 500 was down 1.37%. US markets made broad based losses with seven out of nine sectors finishing the day in red. Pre-market today, WallStEquities.com reviews these four Drug Manufacturers – Major stocks: GlaxoSmithKline PLC (NYSE: GSK), Merck & Co. Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), and Pfizer Inc. (NYSE: PFE). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

GlaxoSmithKline

Brentford, the UK headquartered GlaxoSmithKline PLC’s stock finished Monday’s session 2.37% lower at $39.92. A total volume of 2.70 million shares was traded. The Company’s shares have advanced 6.65% over the previous three months. The stock is trading above its 200-day moving average by 4.16%. Furthermore, shares of GlaxoSmithKline, which engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide, have a Relative Strength Index (RSI) of 38.61. Get the full research report on GSK for free by clicking below at:

www.wallstequities.com/registration/?symbol=GSK

Merck

Shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. ended at $61.08, down 0.63% from the last trading session. The stock recorded a trading volume of 8.90 million shares. The Company’s shares have gained 13.03% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 2.28% and 4.39%, respectively. Moreover, shares of the Company, which provides healthcare solutions worldwide¸ have an RSI of 51.30. Gain free access to the research report on MRK at:

www.wallstequities.com/registration/?symbol=MRK

Novartis

Basel, Switzerland headquartered Novartis AG’s stock ended yesterday’s session 1.37% lower at $74.03 with a total trading volume of 1.44 million shares. The stock is trading below its 50-day moving average by 3.43%. Additionally, shares of Novartis, which researches, develops, manufactures, and markets a range of healthcare products worldwide, have an RSI of 40.67.

On May 29th, 2018, research firm HSBC Securities downgraded the Company’s stock rating from ‘Buy’ to ‘Hold’. Register for your free report coverage on NVS at:

www.wallstequities.com/registration/?symbol=NVS

Pfizer

On Monday, shares in New York headquartered Pfizer Inc. recorded a trading volume of 16.77 million shares. The stock finished the day 0.36% lower at $36.38. The Company’s shares have advanced 6.47% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 0.92% and 1.08%, respectively. Furthermore, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have an RSI of 51.16.

On June 08th, 2018, research firm Cantor Fitzgerald initiated an ‘Overweight’ rating on the Company’s stock, with a target price of $45 per share. Get the free research report on PFE at:

www.wallstequities.com/registration/?symbol=PFE

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 503713